US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy Ruchika Sharma21 Nov 2023 2:30 PM ISTThe therapy was originally co-developed by bluebird bio but following its spin-off in 2021 became part of 2seventy's portfolio.
Post USFDA nod, Bluebird Bio USD 2.8 million gene therapy becomes most expensive drug Ruchika Sharma19 Aug 2022 4:32 PM ISTBluebird has pitched Zynteglo as a potential one-time treatment that could do away with the need for transfusions, resulting in savings for patients...
USFDA panel backs Bluebird bio gene therapy for blood disorder Ruchika Sharma12 Jun 2022 12:00 PM ISTThe FDA is expected to decide on beti-cel's fate by Aug. 19 and eli-cel's by Sept. 16. The agency is not required to follow its advisers'...
Bristol-Myers Squibb gets USFDA nod to multiple myeloma therapy Ruchika Sharma29 March 2021 10:15 AM ISTNew Delhi: The U.S. Food and Drug Administration has approved Bristol-Myers Squibb Co and bluebird bio Inc's multiple myeloma therapy, ide-cel,...
Bristol Myers Squibb gets EMA validation for Idecabtagene Vicleucel, CC-486 Ruchika Sharma25 May 2020 3:53 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Applications (MAA)...
